Cargando…

Minimally effective concentration of zoledronic acid to suppress osteoclasts in vitro

Zoledronic acid is regarded as the most potent bisphosphonate and is widely used in patients with osteoporosis; however, its side effects, including acute-phase reactions, gastrointestinal complaints, renal dysfunction and bisphosphonate-associated osteonecrosis impair the safety and quality of life...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Pengfei, Zhao, Zongmao, Wang, Litao, Jin, Xianhui, Shen, Yaxin, Nan, Chengrui, Liu, Hanjie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2018
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5996712/ https://www.ncbi.nlm.nih.gov/pubmed/29904413 http://dx.doi.org/10.3892/etm.2018.6120

Ejemplares similares

A ball-slide-type interbody distractor is effective in posterior reduction and internal fixation for patients with mid- to high-grade isthmic spondylolisthesis enrolled in a randomized clinical trial
por: Li, Pengfei, et al.
Publicado: (2019)

How zoledronic acid improves osteoporosis by acting on osteoclasts
por: Wang, Biao, et al.
Publicado: (2022)

Tetramethylpyrazine induces differentiation of human umbilical cord-derived mesenchymal stem cells into neuron-like cells in vitro
por: NAN, CHENGRUI, et al.
Publicado: (2016)

Zoledronate suppressed angiogenesis and osteogenesis by inhibiting osteoclasts formation and secretion of PDGF-BB
por: Gao, Si-yong, et al.
Publicado: (2017)

Zoledronic Acid Is Not Equally Potent on Osteoclasts Generated From Different Individuals
por: Møller, Anaïs M J, et al.
Publicado: (2020)

Reactive oxygen species are required for zoledronic acid-induced apoptosis in osteoclast precursors and mature osteoclast-like cells
por: Tai, Ta-Wei, et al.
Publicado: (2017)

A variability in response of osteoclasts to zoledronic acid is mediated by smoking-associated modification in the DNA methylome
por: Tan, Qihua, et al.
Publicado: (2023)

Monosialoteterahexosyl ganglioside induces the differentiation of human umbilical cord-derived mesenchymal stem cells into neuron-like cells
por: NAN, CHENGRUI, et al.
Publicado: (2015)

Zoledronic acid prevents disuse osteopenia and augments gene expression of osteoclastic differentiation markers in mice
por: Vegger, Jens Bay, et al.
Publicado: (2018)

Various pathways of zoledronic acid against osteoclasts and bone cancer metastasis: a brief review
por: Wang, Lianwei, et al.
Publicado: (2020)

Zoledronate Enhances Osteocyte-Mediated Osteoclast Differentiation by IL-6/RANKL Axis
por: Kim, Hyung Joon, et al.
Publicado: (2019)

The Capacity of Magnesium to Induce Osteoclast Differentiation Is Greatly Enhanced by the Presence of Zoledronate
por: Ricchiuto, Silvia, et al.
Publicado: (2023)

Combination of Melatonin and Zoledronic Acid Suppressed the Giant Cell Tumor of Bone in vitro and in vivo
por: Wang, Xudong, et al.
Publicado: (2021)

Zoledronic acid promotes osteoclasts ferroptosis by inhibiting FBXO9-mediated p53 ubiquitination and degradation
por: Qu, Xingzhou, et al.
Publicado: (2021)

Inhibition Effect of Zoledronate on the Osteoclast Differentiation of RAW264.7 Induced by Titanium Particles
por: Zhao, Wenhan, et al.
Publicado: (2021)

Synaptic Plasticity of Human Umbilical Cord Mesenchymal Stem Cell Differentiating into Neuron-like Cells In Vitro Induced by Edaravone
por: Shi, Yunpeng, et al.
Publicado: (2018)

Effect of Denosumab on the Change of Osteoclast Precursors Compared to Zoledronate Treatment in Postmenopausal Women with Osteoporosis
por: Kong, Sung Hye, et al.
Publicado: (2022)

Zoledronic acid inhibits osteoclast differentiation and function through the regulation of NF-κB and JNK signalling pathways
por: Huang, Xiao-Lin, et al.
Publicado: (2019)

Zoledronic Acid in a Mouse Model of Human Fibrous Dysplasia: Ineffectiveness on Tissue Pathology, Formation of “Giant Osteoclasts” and Pathogenetic Implications
por: Corsi, Alessandro, et al.
Publicado: (2020)

Simonkolleite Coating on Poly(Amino Acids) to Improve Osteogenesis and Suppress Osteoclast Formation in Vitro
por: Li, Shuyang, et al.
Publicado: (2019)

Suppression Effect of Astaxanthin on Osteoclast Formation In Vitro and Bone Loss In Vivo
por: Hwang, Yun-Ho, et al.
Publicado: (2018)

Arachidonic Acid and Docosahexaenoic Acid Suppress Osteoclast Formation and Activity in Human CD14+ Monocytes, In vitro
por: Kasonga, Abe E., et al.
Publicado: (2015)

SPHK Inhibitors and Zoledronic Acid Suppress Osteoclastogenesis and Wear Particle-Induced Osteolysis
por: Gu, Minghui, et al.
Publicado: (2022)

A small molecular inhibitor of LRRK1 identified by homology modeling and virtual screening suppresses osteoclast function, but not osteoclast differentiation, in vitro
por: Si, Mingjue, et al.
Publicado: (2019)

Zoledronic Acid-Loaded β-TCP Inhibits Tumor Proliferation and Osteoclast Activation: Development of a Functional Bone Substitute for an Efficient Osteosarcoma Treatment
por: Kameda, Yuka, et al.
Publicado: (2021)

Cryoablation combined with zoledronic acid in comparison with cryoablation and zoledronic acid alone in the treatment of painful bone metastases
por: LI, FENQIANG, et al.
Publicado: (2014)

Intracerebral hemorrhage alters α2δ1 and thrombospondin expression in rats
por: Wang, Bingqian, et al.
Publicado: (2022)

In vitro synergistic cytoreductive effects of zoledronic acid and radiation on breast cancer cells
por: Ural, A Ugur, et al.
Publicado: (2006)

Zoledronic acid inhibits vasculogenic mimicry in murine osteosarcoma cell line in vitro
por: Fu, Dehao, et al.
Publicado: (2011)

Dose-dependent inhibitory effects of zoledronic acid on osteoblast viability and function in vitro
por: HUANG, XIN, et al.
Publicado: (2016)

Zoledronic acid in vivo increases in vitro proliferation of rat mesenchymal stromal cells
por: Heino, Terhi J, et al.
Publicado: (2016)

Zoledronic acid alters hematopoiesis and generates breast tumor-suppressive bone marrow cells
por: Ubellacker, Jessalyn M., et al.
Publicado: (2017)

The anti-tumour effects of zoledronic acid
por: Zekri, Jamal, et al.
Publicado: (2014)

Zoledronic Acid–Induced Interface Dermatitis
por: Succaria, Farah, et al.
Publicado: (2015)

The effects of seeding density and osteoclastic supplement concentration on osteoclastic differentiation and resorption
por: Remmers, Stefan J.A., et al.
Publicado: (2022)

Cost-Effectiveness of Sequential Teriparatide/Zoledronic Acid Compared With Zoledronic Acid Monotherapy for Postmenopausal Osteoporotic Women in China
por: You, Ruxu, et al.
Publicado: (2022)

Cost-Effectiveness of Sequential Denosumab/Zoledronic Acid Compared With Zoledronic Acid Monotherapy for Postmenopausal Osteoporotic Women in China
por: You, Ruxu, et al.
Publicado: (2022)

Zoledronic acid sequential to teriparatide may promote greater inhibition of bone resorption than zoledronic acid alone
por: Giveon, Sharon, et al.
Publicado: (2023)

Administration of zoledronic acid alleviates osteoporosis in HIV patients by suppressing osteoclastogenesis via regulating RANKL expression
por: Lin, Wei, et al.
Publicado: (2021)

Retinoic Acid Increases Proliferation of Human Osteoclast Progenitors and Inhibits RANKL-Stimulated Osteoclast Differentiation by Suppressing RANK
por: Hu, Lijuan, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_3r4kedumdftqdj93nv6mhhmu13